几十年来，治疗性癌症疫苗一直是研究的主题，作为应对恶性肿瘤的潜在新武器。他们的目标是诱导持久有效的抗肿瘤免疫反应，能够介导肿瘤消退、防止肿瘤进展、根除微小残留病，同时避免重大不良反应。新疫苗技术和抗原预测方法的发展导致癌症疫苗功效的显着提高。然而，为了成功临床应用，仍需要克服某些障碍，特别是肿瘤介导的免疫抑制和逃逸机制。在这篇综述中，我们介绍了治疗性癌症疫苗，随后讨论了下一代癌症疫苗和现有免疫疗法的组合方法，特别是免疫检查点抑制剂 (ICIs) 和过继性细胞转移/基于细胞的免疫疗法。版权所有 © 2024。由 Elsevier Inc. 出版。

Therapeutic cancer vaccines have been a subject of research for several decades as potential new weapons to tackle malignancies. Their goal is to induce a long-lasting and efficient antitumour-directed immune response, capable of mediating tumour regression, preventing tumour progression, and eradicating minimal residual disease, while avoiding major adverse effects. Development of new vaccine technologies and antigen prediction methods has led to significant improvements in cancer vaccine efficacy. However, for their successful clinical application, certain obstacles still need to be overcome, especially tumour-mediated immunosuppression and escape mechanisms. In this review, we introduce therapeutic cancer vaccines and subsequently discuss combination approaches of next-generation cancer vaccines and existing immunotherapies, particularly immune checkpoint inhibitors (ICIs) and adoptive cell transfer/cell-based immunotherapies.Copyright © 2024. Published by Elsevier Inc.